Status:
RECRUITING
Hemostasis in Liver Cirrhosis and Hepatocellular Cancer
Lead Sponsor:
Region Stockholm
Collaborating Sponsors:
Sahlgrenska University Hospital
Conditions:
Hemostasis in Decompensated Liver Cirrhosis
Inflammation in Decompensated Liver Cirrhosis
Eligibility:
All Genders
18+ years
Brief Summary
Evaluating hemostasis in decompensated liver cirrhosis with novel hemostatic assays.
Detailed Description
The rebalanced hemostasis in liver cirrhosis is vulnerable and patients are prone to both bleeding and thrombosis. There are today no gold standard for evaluating the hemostasis and we will evaluate n...
Eligibility Criteria
Inclusion
- Patients with decompensated liver cirrhosis
- 18 years or older.
- Healthy individuals 18 years or older will serve as controls.
Exclusion
- • Extrahepatic malignancy or recurrence of such within the last year.
- Diagnosis of non-cirrhotic coagulopathy, coagulation disorder or thrombophilia prior to inclusion.
- Diagnosis of hematological disease such as hematologic malignancies, non-cirrhotic thrombocytopenia or thrombocytosis, Polycytemia Vera, hemoglobinopathies
- Previous liver transplantation.
- Transfusions the last 7 days.
- Treatment with platelet inhibitors or anticoagulant except for prophylactic dosage of LMWH. If a prophylactic dose of LMWH has been used study sampling with addition of antiFXa must be taken \>12 hours after the last injection.
Key Trial Info
Start Date :
December 2 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2028
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06212635
Start Date
December 2 2022
End Date
December 1 2028
Last Update
January 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Karolinska University Hospital
Stockholm, Huddinge, Sweden, 14186